J
Jim Cassidy
Researcher at University of Glasgow
Publications - 225
Citations - 22059
Jim Cassidy is an academic researcher from University of Glasgow. The author has contributed to research in topics: Colorectal cancer & Capecitabine. The author has an hindex of 64, co-authored 217 publications receiving 20828 citations. Previous affiliations of Jim Cassidy include Western Infirmary & University of Aberdeen.
Papers
More filters
Journal ArticleDOI
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Leonard B. Saltz,Stephen Clarke,Eduardo Díaz-Rubio,Werner Scheithauer,Arie Figer,Ralph Wong,Sheryl Koski,Mikhail Lichinitser,T. Yang,Fernando Rivera,Félix Couture,Florin Sirzen,Jim Cassidy +12 more
TL;DR: The addition of bevacizumab to oxaliplatin-based chemotherapy significantly improved PFS in this first-line trial in patients with MCRC.
Journal ArticleDOI
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard,Salvatore Siena,Jim Cassidy,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Kelly S. Oliner,Michael S. Wolf,Jennifer Gansert +19 more
TL;DR: This study demonstrated that panitumumab-FOLFOX4 was well tolerated and significantly improved PFS in patients with WT KRAS tumors and underscores the importance of KRAS testing for patients with mCRC.
Journal ArticleDOI
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Chris Twelves,A. Wong,M. Nowacki,Markus Abt,Howard A. Burris,Alfredo Carrato,Jim Cassidy,Andrés Cervantes,Jan Fagerberg,Vassilis Georgoulias,Fares Husseini,Duncan I. Jodrell,P. Koralewski,Hendrik Kröning,Jean A. Maroun,Norbert Marschner,Joseph McKendrick,M. Pawlicki,Riccardo Rosso,Johannes Schüller,Jean-François Seitz,Borut Stabuc,Jerzy Tujakowski,Guy van Hazel,Jerzy Zaluski,Werner Scheithauer +25 more
TL;DR: Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.
Journal ArticleDOI
Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study
Eric Van Cutsem,Chris Twelves,Jim Cassidy,David Allman,Emilio Bajetta,Michael Boyer,Roland Bugat,Michael Findlay,Stefan Frings,Michaela Jahn,Joseph McKendrick,Osterwalder B,Gumersindo Perez-Manga,Riccardo Rosso,Philippe Rougier,Wolff Schmiegel,Jean-François Seitz,Paul M. Thompson,Jose María Vieitez,C Weitzel,Peter Harper +20 more
TL;DR: Oral capecitabine achieved an at least equivalent efficacy compared with IV 5-FU/LV as first-line treatment for metastatic colorectal cancer and demonstrated clinically meaningful safety advantages and the convenience of an oral agent.
Journal ArticleDOI
Randomized Intergroup Trial of Cisplatin–Paclitaxel Versus Cisplatin–Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results
Martine Piccart,Kamma Bertelsen,Keith James,Jim Cassidy,Constantino Mangioni,Ernst Simonsen,Gavin Stuart,Stan B. Kaye,Ignace Vergote,René Blom,R. Grimshaw,Ronald J. Atkinson,Ken D. Swenerton,Claes G. Tropé,M. Nardi,Janne Kærn,Salvatore Tumolo,Petra Timmers,Josee Anne Roy,François Lhoas,Berit Lindvall,Monica Bacon,Angelo Birt,Joern Erik Andersen,Benny Zee,James Paul,Benoit Baron,Sergio Pecorelli +27 more
TL;DR: There is strong and confirmatory evidence from two large randomized phase III trials to support paclitaxel-cisplatin as the new standard regimen for treatment of patients with advanced ovarian cancer.